EMA Authorised: Forxiga (dapagliflozin propanediol monohydrate) — AstraZeneca AB

View source ↗

Summary

EMA authorised Forxiga (dapagliflozin propanediol monohydrate) for type 2 diabetes mellitus, heart failure (systolic), and chronic kidney disease. AstraZeneca A…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Heart Failure
• Type 2 Diabetes Mellitus

Drugs mentioned

• Forxiga (dapagliflozin)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2;Heart Failure, Systolic;Heart Failure;Renal Insufficiency, Chronic. MAH: AstraZeneca AB. Decision date: 12/03/2026